The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

Disclosed is a method of storing a thioepoxy compound and a method of preparing a thioepoxy based optical material using the thioepoxy compound. Particularly, a method of preparing a high-quality thioepoxy based optical material having superior color and thermal stability and less time-dependent change, and being colorless and transparent by inhibiting time-dependent change of the thioepoxy compound during storage is disclosed. In addition, a method of storing the thioepoxy compound for an optical material, the thioepoxy compound having a water content of 500 to 2,500 ppm and stored at 78 to 10 C., and a method of preparing the thioepoxy based optical material, the method including polymerizing a polymerizable composition including the stored thioepoxy compound, are provided. The high-quality thioepoxy based optical material, which is colorless and transparent, prepared according to the present invention may be broadly used in a variety of fields as a substitute for conventional optical materials.

Disclosed is a method of storing a thioepoxy compound and a method of preparing a thioepoxy based optical material using the thioepoxy compound. Particularly, a method of preparing a high-quality thioepoxy based optical material having superior color and thermal stability and less time-dependent change, and being colorless and transparent by inhibiting time-dependent change of the thioepoxy compound during storage is disclosed. In addition, a method of storing the thioepoxy compound for an optical material, the thioepoxy compound having a water content of 500 to 2,500 ppm and stored at 78 to 10 C., and a method of preparing the thioepoxy based optical material, the method including polymerizing a polymerizable composition including the stored thioepoxy compound, are provided. The high-quality thioepoxy based optical material, which is colorless and transparent, prepared according to the present invention may be broadly used in a variety of fields as a substitute for conventional optical materials.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

According to the present invention, a composition for an optical material can be provided, which is characterized by containing an episulfide compound having a value of turbidity in acetone of 3.0 ppm or less. According to a preferred embodiment of the present invention, a composition for an optical material can be provided, which comprises: (a) a compound (an episulfide compound) which has a structure represented by formula (1) and has a value of turbidity in acetone of 3.0 ppm or less; (b) a polyisocyanate compound; and (c) a polythiol compound.

##STR00001##

(In the formula, m represents an integer of 0 to 4; and n represents an integer of 0 or 1.)

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.